Cart
sales@molnova.com
Telisotuzumab
CAS No. 1781223-80-0
Telisotuzumab( —— )
Catalog No. M36894 CAS No. 1781223-80-0
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 565 | Get Quote |
|
| 5MG | 886 | Get Quote |
|
| 10MG | 1416 | Get Quote |
|
| 25MG | 2015 | Get Quote |
|
| 50MG | 2732 | Get Quote |
|
| 100MG | 3537 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTelisotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTelisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
-
DescriptionTelisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity.
-
In Vitro——
-
In VivoAnimal Model:SCID mice with Hs746T cells Dosage:2.5-40 mg/kg Administration:i.p., twice a week, 90 days Result:Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met/HGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1781223-80-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.?
molnova catalog
related products
-
palovarotene
Palovarotene is an agonist of nuclear retinoic acid receptor γ (RAR-γ).
-
Tivantinib
Tivantinib (ARQ-197)?is a potent, selective, non-ATP-competitive inhibitor of c-Met with Ki of 355 nM.
-
Ningetinib
Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
